J. Schlesinger

发表

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

Gregory D. Gromowski, A. Barrett, J. Roehrig, 2007, Journal of Virology.

Myoglobinuria associated with herpes-group viral infections.

J. Schlesinger, D. Gandara, D. Gandara, 1978, Archives of internal medicine.

Pathoanatomic, pathophysiologic and clinical correlations in endocarditis (second of two parts).

J. Schlesinger, L. Weinstein, 1974, The New England journal of medicine.

Pathoanatomic, pathophysiologic and clinical correlations in endocarditis (first of two parts).

J. Schlesinger, L. Weinstein, 1974, The New England journal of medicine.

The effect of halothane on in vitro human neutrophil chemotaxis

J. Schlesinger, A. Ross, 1977, Experientia.

Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human FcγRIA (CD64) or FcγRIIA (CD32)

Robert C. Rose, Xia Jin, J. Schlesinger, 2006, Journal of Virology.

Difference between the Abilities of Human Fcγ Receptor-Expressing CV-1 Cells To Neutralize American and Asian Genotypes of Dengue Virus 2

J. Schlesinger, G. Comach, R. Rose, 2008, Clinical and Vaccine Immunology.

Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

J. Schlesinger, S. Dewhurst, Ramil E. Sapinoro, 2008, Virology.

Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody.

J. Schlesinger, E. Walsh, J. R. Putnak, 1990, The Journal of general virology.

Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.

A. Rothman, J. Schlesinger, I. Kurane, 1994, The American journal of tropical medicine and hygiene.

The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

J. Schlesinger, M. Foltzer, S. Chapman, 1993, Virology.

Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

J. Schlesinger, E. Walsh, C. Hall, 1989, The Journal of general virology.

Short Report: An Automated Dengue Virus Microneutralization Plaque Assay Performed in Human Fc γ Receptor-expressing CV-1 Cells

J. Schlesinger, R. Rose, W. W. S. I. Rodrigo, 2008 .

Treatment of infective endocarditis--1973.

J. Schlesinger, L. Weinstein, 1973, Progress in cardiovascular diseases.

Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies

J. Schlesinger, E. Walsh, M. W. Brandriss, 1984, Infection and immunity.

Partial N-terminal amino acid sequences of three nonstructural proteins of two flaviviruses.

J. H. Strauss, R. Aebersold, J. Schlesinger, 1986, Virology.

Immunogenicity of a purified fragment of 17D yellow fever envelope protein.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1990, The Journal of infectious diseases.

Antibody‐mediated infection of macrophages and macrophage‐like cell lines with 17D‐yellow fever virus

J. Schlesinger, M. W. Brandriss, 1981, Journal of medical virology.

A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.

J. Schlesinger, R. Rose, Xia Jin, 2010, Vaccine.

Propionibacterium acnes meningitis in a previously normal adult.

J. Schlesinger, A. Ross, 1977, Archives of internal medicine.

Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide.

T. Monath, J. Schlesinger, R. Kinney, 1983, The Journal of general virology.

Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens

C. B. Cropp, T. Monath, J. Schlesinger, 1986, Journal of clinical microbiology.

Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.

T. Monath, J. Schlesinger, M. W. Brandriss, 1983, Virology.

Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection.

J. Schlesinger, M. W. Brandriss, 1981, Journal of immunology.

Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1

C. B. Cropp, T. Monath, J. Schlesinger, 1986, Journal of virology.

Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.

J. Schlesinger, E. Walsh, P. Cote, 1986, The Journal of general virology.

Purification and characterization of the respiratory syncytial virus fusion protein.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1985, The Journal of general virology.

Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1984, The Journal of general virology.

Purification and Characterization of GP 90 , One of the Envelope Glycoproteins of Respiratory Syncytial Virus

J. Schlesinger, E. Walsh, M. W. Brandriss, 1984 .

Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1984, The Journal of general virology.

Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.

C. Huang, J. Roehrig, J. Schlesinger, 2014, Virology.

Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence.

C. B. Cropp, T. Monath, J. Schlesinger, 1984, The American journal of tropical medicine and hygiene.

Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses.

J. Schlesinger, V. Deubel, M. Girard, 1991, Virology.

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells

J. Schlesinger, R. Rose, Z. Kou, 2008, Journal of medical virology.

Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.

J. Schlesinger, E. Walsh, M. Briselli, 1986, The Journal of general virology.

Homogeneity among Senegalese strains of yellow fever virus.

J. Schlesinger, M. Cornet, V. Deubel, 1985, The American journal of tropical medicine and hygiene.

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.

J. Schlesinger, D. Morens, J. Hugnot, 1992, Virology.

Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1987, The Journal of general virology.

Staphylococcal induced toxic epidermal necrolysis in an adult: case report.

J. Schlesinger, 1977, Military Medicine.

Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Soila Sukupolvi-Petty, M. Diamond, J. Schlesinger, 2009, Virology.

Dengue vaccine development and dengue viral neutralization and enhancement assays

J. Schlesinger, R. Rose, Xia Jin, 2009, Antiviral therapy.

Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.

J. Schlesinger, E. Walsh, C. Hall, 1987, The Journal of infectious diseases.

Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes.

A. Barrett, J. Schlesinger, T. N. Ledger, 1997, The Journal of general virology.

Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis

J. Schlesinger, M. Bray, C. Lai, 1990, Journal of virology.

Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b.

J. Schlesinger, J. R. Putnak, 1990, The Journal of general virology.

Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.

J. Schlesinger, E. Walsh, M. W. Brandriss, 1985, Journal of immunology.

Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain).

J. Schlesinger, L. Dalgarno, R. Weir, 1987, Virology.

Primary Human Splenic Macrophages, but Not T or B Cells, Are the Principal Target Cells for Dengue Virus Infection In Vitro

J. Schlesinger, R. Rose, Z. Kou, 2007, Journal of Virology.

Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus.

J. Schlesinger, E. Henchal, L. S. Henchal, 1988, The Journal of general virology.

Primary human endothelial cells support direct but not antibody‐dependent enhancement of dengue viral infection

J. Schlesinger, Z. Kou, Xia Jin, 2009, Journal of medical virology.

Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model

J. Schlesinger, A. Davidson, Xiaoshan Jiang, 2003, Journal of Virology.

Antibody-mediated infection of P388D1 cells with 17D yellow fever virus: effects of chloroquine and cytochalasin B.

J. Schlesinger, M. W. Brandriss, 1984, The Journal of general virology.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

J. Roehrig, J. Schlesinger, C. Blair, 2012, Antiviral research.

Attenuation of wild-type yellow fever virus by passage in HeLa cells.

A. Barrett, E. Gould, C. B. Cropp, 1990, The Journal of general virology.

17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor.

J. Schlesinger, M. W. Brandriss, 1983, The Journal of general virology.

Prospects for a virus non-structural protein as a subunit vaccine.

A. Barrett, J. Schlesinger, C. A. Gibson, 1988, Vaccine.

Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes.

M. Beltramello, M. Diamond, J. Schlesinger, 2011, Virology.

An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells.

J. Schlesinger, R. Rose, Xia Jin, 2009, The American journal of tropical medicine and hygiene.

New approaches to flavivirus vaccine development.

J. Schlesinger, J. R. Putnak, K. Eckels, 1992, Biotechnology.

Responses of elderly subjects to a new subunit influenza virus vaccine.

J. Schlesinger, R. Douglas, M. W. Brandriss, 1982, The Journal of infectious diseases.

Streptococcal meningitis after myelography.

J. Schlesinger, I. Salit, G. McCormack, 1982, Archives of neurology.

Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis.

J. Schlesinger, S. Chapman, 1995, The Journal of general virology.

Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus.

J. Schlesinger, S. Chapman, 1999, Virology.

Comparative immunochemical and biological analysis of African and South American yellow fever viruses

J. Schlesinger, V. Deubel, J. Digoutte, 2005, Archives of Virology.

Flavivirus nonstructural protein NS1: Complementary surprises

J. Schlesinger, 2006, Proceedings of the National Academy of Sciences.

Growth of measles virus in a human macrophagelike cell line: U937.

J. Schlesinger, S. Chapman, M. W. Brandriss, 1982, The American journal of pathology.

Difference between the Abilities of Human Fcγ Receptor-Expressing CV-1 Cells To Neutralize American and Asian Genotypes of Dengue Virus 2

J. Schlesinger, G. Comach, R. Rose, 2013, Clinical and Vaccine Immunology.